Nicolas Van de Velde
机构: Health Economics and Outcomes Research, Moderna Inc.
每年引用次数
引用次数
引用: 1,948
H-指数: 19
I10-指数 : 30
出版物: 102
Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries:
Christophe Sauboin , Laure-Anne Van Bellinghen , Nicolas Van De Velde , Ilse Van Vlaenderen
MDM Policy & Practice 4 ( 2) 2381468319873324
1
2019
Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study
Christophe J. Sauboin , Laure-Anne Van Bellinghen , Nicolas Van De Velde , Ilse Van Vlaenderen
Malaria Journal 14 ( 1) 524 -524
7
2015
Vaccine preparation time, errors, satisfaction, and preference of prefilled syringes versus RSV vaccines requiring reconstitution: randomized, time and motion study
Darshan Mehta , Samantha Kimball-Carroll , DaynaR Clark , Serena Fossati
Journal of Medical Economics ( just-accepted) 1 -16
2024
Pneumokoki konjugeeritud vaktsiiniga vaktsineerimise kulutõhusus Eesti vastsündinute kohordis
Nicolas Van de Velde , Oscar Leeuwenkamp , Jan Olbrecht , Benedetto Simone
Eesti Arst
2017
Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Olivia Hayward , Nicolas Van de Velde , Erin Arthurs , Debbie Becker
PLOS ONE 16 ( 2)
2021
Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries.
Gaelle Nachbaur , Paolo Rizzini , Laurent Finkielsztejn , Nicolas Van de Velde
Sexually Transmitted Infections
2021
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.
Nicolas Van de Velde , Marc Brisson , Marie-Claude Boily
Vaccine 28 ( 33) 5473 -5484
81
2010
Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Emmanuelle Delgleize , Oscar Leeuwenkamp , Eleni Theodorou , Nicolas Van de Velde
BMJ Open 6 ( 11)
20
2016
Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?
Mélanie Drolet , Marie-Claude Boily , Nicolas Van de Velde , Eduardo L. Franco
PLoS ONE 8 ( 6) e67072
8
2013
Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries.
Patricia de los Rios , Chinyere Okoli , Yogesh Punekar , Brent Allan
Preventive Medicine 139 106182
33
2020
Regional differences in perceived treatments needs and priorities in relation to antiretroviral therapy among people living with HIV in 25 countries.
Chinyere Okoli , Nicolas Van de Velde , Brent Allan , W. David Hardy
Preventive Medicine 142 106372
2021
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Marc Brisson , Nicolas Van de Velde , Philippe De Wals , Marie-Claude Boily
Vaccine 25 ( 29) 5399 -5408
169
2007
Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
Nicolas Van de Velde , Marie-Claude Boily , Mélanie Drolet , Eduardo L. Franco
Journal of the National Cancer Institute 104 ( 22) 1712 -1723
162
2012
Treatment aspirations and attitudes towards innovativemedications among people living with HIV in 25 countries
Patricia de los Rios , Chinyere Okoli , Benjamin Young , Brent Allan
Population Medicine 2
2
2020
Quantifying people living with HIV who would benefit from an alternative to daily oral therapy: Perspectives from HIV physicians and people living with HIV
Laura Clark , Chitra Karki , Josh Noone , Jenny Scherzer
Population Medicine 2 1 -18
2
2020
Differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 middle-income and high-income countries: Findings from the 2019 Positive Perspectives Survey
Chinyere Okoli , Nicolas Van de Velde , Garry Brough , W. David Hardy
Population Medicine 2 1 -13
2020
1018. Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness
Ian Jacob , Debbie Becker , Amy Lee , Olivia Hayward
Open Forum Infectious Diseases 7
2020
1017. Haves vs. Have-Nots in Healthcare Communication: Examining the Paradox Where PLHIV Who Need Quality Discussions with their Providers the Most, Access it the Least
Patricia De Los Rios , Benjamin Young , Marvelous Muchenje , Nicolas Van de Velde
Open Forum Infectious Diseases 7
2020
1045. Treatment-Related Physical, Emotional, and Psychosocial Challenges and their Impact on Indicators of Quality of Life
Patricia De Los Rios , Brent Allan , Chinyere Okoli , Benjamin Young
Open Forum Infectious Diseases 7
2020
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
Melissa A Penny , Robert Verity , Caitlin A Bever , Christophe Sauboin
The Lancet 387 ( 10016) 367 -375
100
2016